Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics

@article{Highlander2010CurrentPC,
  title={Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics},
  author={Peter Highlander and Graham P. Shaw},
  journal={Therapeutic Advances in Cardiovascular Disease},
  year={2010},
  volume={4},
  pages={43 - 54}
}
With the growing worldwide obesity epidemic, obesity, type 2 diabetes mellitus and hypertension leading to premature cardiovascular events, are increasingly prevalent. Diabetes mellitus is a significant public health concern and more aggressive management of the condition and its complications, particularly cardiovascular disease, is warranted. Endothelial cell dysfunction is now known to be present at the earliest stages of metabolic syndrome, and insulin resistance and may precede the… 

Influences of diabetes on the development and progression of cardiovascular disease

The March/April 2010 issue of the British Journal of Diabetes & Vascular Disease discusses the management of cardiovascular complications in diabetes and introduces myself as a new member of the editorial team of the journal.

Endothelial dysfunction - a major mediator of diabetic vascular disease.

Role of Heme Oxygenases in Cardiovascular Syndromes and Co-morbidities

Each of the six major categories of CVD exhibit features of pathogenesis that hold potential as future therapeutic targets, for modulated heme oxygenase activity.

Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Modifiable and nonmodifiable risk factors associated with metabolic syndrome in the progression of CVD, such as obesity, diabetes, hypertension, dyslipidemia, oxidative stress, inflammation, and adipocytokines are outlined.

Assessment of Microvascular Function in Children and Adolescents with Diabetes and Obesity

Patients with poorly-controlled DM as reflected by latest A1C of ≥ 10% had worse endothelial function as reflected in lower RHI score, which was shown to be a marker of vascular damage.

Protective Effect of Marine Peptides/Toxins in CVD Using Zebrafish Model

This chapter reveals that marine peptides could be used as an antihypertensive agent, and that the zebrafish provides an alternative in vivo model to efficiently evaluate the anti Hypertensive properties of marine peptide.

A Study of Osteoprotegerin in Diabetic Patients as Indicator for Myocardial Infarction

Serum Osteoprotegerin levels were higher in diabetic patients suffering from myocardial infarction, so this parameter could be a risk marker for MI in diabetes patients.

Role of Inflammatory Markers C-reactive Protein,High Sensitivity C-reactive Protein in Diabetes and Its Cardiovascular Complications

This article will introduce recent studies on the relationship among CRP,hs-CRP, diabetes mellitus and cardiovascular diseases.

References

SHOWING 1-10 OF 127 REFERENCES

Endothelial dysfunction in diabetes mellitus

Control of hyperglycemia remains the best way to improve endothelial function and to prevent atherosclerosis and other cardiovascular complications of diabetes.

A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient

In order to optimally reduce the risk for cardiovascular events in the patient with diabetes and hypertension, optimal BP control should be coupled with comprehensive lifestyle modification and aggressive management of dyslipidemia and hyperglycemia.

Vascular Endothelium as a Target of Beraprost Sodium and Fenofibrate for Antiatherosclerotic Therapy in Type 2 Diabetes Mellitus

Vascular endothelium is focused on as a target of the prostaglandin I2 analog beraprost sodium and the peroxisome proliferators-activated receptor α activator fenofibrate for the prevention and treatment of atherosclerosis in patients with type 2 diabetes mellitus.

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

Diabetic Dyslipidemia: Causes and Consequences

A characteristic pattern, termed diabetic dyslipidemia, consists of low high density lipoprotein (HDL), increased triglycerides, and postprandial lipemia, most frequently seen in type 2 diabetes and may be a treatable risk factor for subsequent cardiovascular disease.

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension.

The statins in prevention of coronary heart diseases in type 2 diabetics.

Statin therapy reduced the risk of coronary heart disease in diabetics without CHD and their effects on cholesterol and CRP levels and positive correlation was between CRP and CVD.

The value of irbesartan in the management of hypertension

The data from randomized clinical trials on the efficacy of antihypertensive drugs provides an indication of their real value to patients and observational data from clinical practice and proven end-organ protection in diabetic nephropathy provides further evidence of the true value of irbesartan compared to other ARBs in the treatment of hypertension.
...